HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Enforma contests FTC allegations

This article was originally published in The Tan Sheet

Executive Summary

Pointing to 19 studies as evidence of its Chitozyme weight-loss supplement's efficacy, company says FTC's recent contempt motion is "frivolous" and commission will be unable to provide clear and convincing evidence that Enforma lacks adequate substantiation for its ad claims. Enforma asserts FTC is using an undefined standard for "competent and reliable scientific evidence" and suggests commission should clarify this standard by telling Enforma what studies it considers vital to marketing Chitozyme. Firm says it has turned over to FTC studies on Carb Trapper Plus, and notes its products carry money-back guarantees, thereby refuting FTC's claim that consumers have suffered financial harm (1"The Tan Sheet" Aug. 5, 2002, p. 5). Enforma says it is considering suing FTC if company prevails in present action. Hearing on FTC's contempt motion, preliminary injunction request is scheduled for Sept. 30...

You may also be interested in...

Enforma Carb Trapper Plus Supplement Ad Claims Under FTC Scrutiny

Enforma Natural Products could be hit with civil contempt charges for the third time if FTC determines the firm is making unsubstantiated advertising and marketing claims for its Carb Trapper Plus weight-loss product

ObvioHealth Is Building A New Digital Ecosystem To 'Revolutionize' Trials

Using artificial intelligence and strict data collection protocol, ObvioHealth hopes to digitize clinical trials with the assistance of medical devices and consumer technology.

Leo’s Tralokinumab Among 11 New Approval Hopefuls In EU

The developers of eleven new drugs could learn this week whether the European Medicines Agency will set them on course for pan-EU marketing approval.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts